Literature DB >> 34310709

Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer.

Sigve Nakken1,2, Vladislav Saveliev3, Oliver Hofmann3, Pål Møller1, Ola Myklebost1,4,5, Eivind Hovig1,6.   

Abstract

The value of high-throughput germline genetic testing is increasingly recognized in clinical cancer care. Disease-associated germline variants in cancer patients are important for risk management and surveillance, surgical decisions and can also have major implications for treatment strategies since many are in DNA repair genes. With the increasing availability of high-throughput DNA sequencing in cancer clinics and research, there is thus a need to provide clinically oriented sequencing reports for germline variants and their potential therapeutic relevance on a per-patient basis. To meet this need, we have developed the Cancer Predisposition Sequencing Reporter (CPSR), an open-source computational workflow that generates a structured report of germline variants identified in known cancer predisposition genes, highlighting markers of therapeutic, prognostic and diagnostic relevance. A fully automated variant classification procedure based on more than 30 refined American College of Medical Genetics and Genomics (ACMG) criteria represents an integral part of the workflow. Importantly, the set of cancer predisposition genes profiled in the report can be flexibly chosen from more than 40 virtual gene panels established by scientific experts, enabling customization of the report for different screening purposes and clinical contexts. The report can be configured to also list actionable secondary variant findings, as recommended by ACMG. CPSR demonstrates comparable sensitivity and specificity for the detection of pathogenic variants when compared to other algorithms in the field. Technically, the tool is implemented in Python/R, and is freely available through Docker technology. Source code, documentation, example reports and installation instructions are accessible via the project GitHub page: https://github.com/sigven/cpsr.
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Entities:  

Keywords:  bioinformatics workflow; cancer germline testing; clinical decision support; precision cancer medicine; variant interpretation

Year:  2021        PMID: 34310709     DOI: 10.1002/ijc.33749

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Germline POT1 Deregulation Can Predispose to Myeloid Malignancies in Childhood.

Authors:  Pia Michler; Anne Schedel; Martha Witschas; Ulrike Anne Friedrich; Rabea Wagener; Juha Mehtonen; Triantafyllia Brozou; Maria Menzel; Carolin Walter; Dalileh Nabi; Glen Pearce; Miriam Erlacher; Gudrun Göhring; Martin Dugas; Merja Heinäniemi; Arndt Borkhardt; Friedrich Stölzel; Julia Hauer; Franziska Auer
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

2.  A rare PALB2 germline variant causing G2/M cell cycle arrest is associated with isolated myelosarcoma in infancy.

Authors:  Angelina Beer; Ricardo Beck; Anne Schedel; Malte von Bonin; Jörn Meinel; Ulrike Anne Friedrich; Maria Menzel; Meinolf Suttorp; Sebastian Brenner; Guido Fitze; Björn Lange; Ralf Knöfler; Julia Hauer; Franziska Auer
Journal:  Mol Genet Genomic Med       Date:  2021-08-12       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.